Liver Cancer News and Research RSS Feed - Liver Cancer News and Research

Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.
ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX, a clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, today announced that it has dosed in New Zealand the first patient in a Phase IIb/III clinical trial of ABX203 which is taking place in several countries of the Asia-Pacific region. [More]
Scientists detect new molecule that contributes to development of liver fibrosis

Scientists detect new molecule that contributes to development of liver fibrosis

Liver fibrosis, which is the progressive formation of scar tissue in the liver, is a massive medical problem. An estimated ten percent of the population is affected by liver fibrosis or its corresponding later stage, liver cirrhosis. A variety of causes can lead to liver fibrosis, the most widely recognized ones being alcohol consumption and virus-induced chronic liver inflammation. [More]
SLU researchers halt fatty liver disease in animal model

SLU researchers halt fatty liver disease in animal model

Doctors believe that up to 30 percent of the U.S. population may have fat accumulation in the liver, known as non-alcoholic fatty liver disease (NAFLD), that can lead to a range of damaging health consequences. [More]
USPTO issues Notice of Allowance to Can-Fite BioPharma for psoriasis patent

USPTO issues Notice of Allowance to Can-Fite BioPharma for psoriasis patent

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for CF101 in the treatment of psoriasis. [More]
GI Society releases video to spread awareness about hepatitis C

GI Society releases video to spread awareness about hepatitis C

As many as 350,000 Canadians could be suffering with hepatitis C, many of whom are unaware that they are infected, thus continuing to spread the virus. Although there is a vaccine to prevent the spread of the hepatitis A and hepatitis B viruses, there is no vaccine for hepatitis C. The good news is that with new treatments, hepatitis C is now a curable disease. [More]
HCV more common in West Africa yet lacks equal attention as HIV/AIDS or Ebola

HCV more common in West Africa yet lacks equal attention as HIV/AIDS or Ebola

More than 180 million people in the world have hepatitis C, compared with the 34 million with HIV/AIDS and the roughly 30,000 who have had Ebola. [More]
41% of the British population unaware of the role of diet in cancer development

41% of the British population unaware of the role of diet in cancer development

Surprising new statistics reveal that 41% of the British population are oblivious to the role that diet plays in the development of cancer - and even those with a family history of the disease are failing to consume potentially "cancer-preventing" compounds in their daily diet. [More]
Researchers develop new MRI-based technique to better detect NAFLD in children

Researchers develop new MRI-based technique to better detect NAFLD in children

Between 5 and 8 million children in the United States have nonalcoholic fatty liver disease (NAFLD), yet most cases go undiagnosed. To help address this issue, researchers at UC San Diego School of Medicine have developed a new magnetic resonance imaging (MRI)-based technique to help clinicians and researchers better detect and evaluate NAFLD in children. [More]
Chemotherapy or immunosuppressive treatment may reactivate HBV

Chemotherapy or immunosuppressive treatment may reactivate HBV

Individuals previously infected with the hepatitis B virus (HBV) who receive chemotherapy or immunosuppressive treatment may be at risk of reactivating the disease according to a summary of report from the Emerging Trends Conference, "Reactivation of Hepatitis B," and published in Hepatology, a journal of the American Association for the Study of Liver Diseases. [More]
Can-Fite BioPharma completes patient enrollment in CF101 Phase II/III psoriasis trial

Can-Fite BioPharma completes patient enrollment in CF101 Phase II/III psoriasis trial

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that all patients enrolled in its Phase II/III psoriasis trial for the Company's drug candidate CF101 have completed the study's 32 week treatment protocol. [More]
International community funding can significantly reduce cancer deaths in LMICs by 2030

International community funding can significantly reduce cancer deaths in LMICs by 2030

Increased annual international community funding of US$18 billion globally could save three million lives per year by 2030 and many more in succeeding decades, [More]
Scientists identify gene mutations that provide better insight into hepatitis-liver cancer link

Scientists identify gene mutations that provide better insight into hepatitis-liver cancer link

Using whole genomic sequencing, scientists from RIKEN in Japan have for the first time demonstrated the profound effect that chronic hepatitis infection and inflammation can have on the genetic mutations found in tumors of the liver, potentially paving the way to a better understanding of the mechanisms through which these chronic infections can lead to cancer. [More]
Using Cultrex BME 2 reduced growth factor to enable long-term culture of human hepatocytes

Using Cultrex BME 2 reduced growth factor to enable long-term culture of human hepatocytes

AMSBIO reports on the recent publication in Cell [1] by Dr Meritxell Huch, Prof Hans Clevers et al. of ground-breaking research using Cultrex BME2 reduced growth factor (organoid growth matrix) to enable long-term (>1 year) culture of genome-stable bipotent stem cells from adult human liver. These results open up new experimental avenues towards the use of human liver material expanded in vitro as an alternative cell source for disease modeling, toxicology studies, drug testing, regenerative medicine and gene therapy. [More]
Quest Diagnostics, CDC partner to identify trends in diagnosis and treatment for viral hepatitis

Quest Diagnostics, CDC partner to identify trends in diagnosis and treatment for viral hepatitis

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced that it will collaborate with the Centers for Disease Control and Prevention to identify trends in screening, diagnosis and treatment for four strains of viral hepatitis in the United States, based on insights revealed by analysis of Quest’s national testing database. [More]
Quest Diagnostics, CDC collaborate to reduce deaths from hepatitis

Quest Diagnostics, CDC collaborate to reduce deaths from hepatitis

Quest Diagnostics, the world's leading provider of diagnostic information services, today announced that it will collaborate with the Centers for Disease Control and Prevention to identify trends in screening, diagnosis and treatment for four strains of viral hepatitis in the United States, based on insights revealed by analysis of Quest's national testing database. [More]
Attaching Epirubicin drug to nanodiamonds eliminates chemoresistant cancer stem cells

Attaching Epirubicin drug to nanodiamonds eliminates chemoresistant cancer stem cells

A study led by the National University of Singapore found that attaching chemotherapy drug Epirubicin to nanodiamonds effectively eliminates chemoresistant cancer stem cells. The findings were first published online in ACS Nano, the official journal of the American Chemical Society, in December 2014. [More]
Researchers reveal key factor in understanding elevated cancer risk linked to gene therapy

Researchers reveal key factor in understanding elevated cancer risk linked to gene therapy

National Institutes of Health researchers have uncovered a key factor in understanding the elevated cancer risk associated with gene therapy. They conducted research on mice with a rare disease similar to one in humans, hoping their findings may eventually help improve gene therapy for humans. Researchers at the National Human Genome Research Institute, part of NIH, published their research in the Jan. 20, 2015, online issue of the Journal of Clinical Investigation. [More]
Using breath tests to diagnose liver diseases: an interview with Larry Cohen

Using breath tests to diagnose liver diseases: an interview with Larry Cohen

It was back in the 1960s that scientists first started to understand that breath could be used to find out different things about diseases and other factors. I’m sure you’re familiar with alcohol breath testing, which was patented back in the ‘50s and has been used since the ‘60s. [More]
Researchers examine how terpenes can inhibit growth of liver cancer cells

Researchers examine how terpenes can inhibit growth of liver cancer cells

As main component of essential oils, terpenes can inhibit the growth of different cancer cells. Researchers from the Ruhr-University Bochum headed by Prof Dr Dr Dr Hanns Hatt have analysed this process in liver cancer cells in detail. [More]

GenSpera reports encouraging results from mipsagargin Phase II study for HCC treatment

GenSpera Inc. today announced the encouraging results of a Phase II study of mipsagargin (G-202), an investigational agent for the treatment of hepatocellular carcinoma (HCC). [More]